Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world.

Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world.

Publication date: Jan 19, 2024

Bacterial infections are not prevalent among patients hospitalized with COVID-19, while unnecessary prescription of antibiotics was commonly observed. This study aimed to determine the impact of procalcitonin testing on antibiotics prescription in the real-world setting. We performed a territory-wide retrospective cohort study involving all laboratory-confirmed patients hospitalized in public hospitals in Hong Kong in 2020 with COVID-19. We determined the prevalence of bacterial co-infections (documented infections within 72 h of admission) and secondary bacterial infections (infections after 72 h of admission) and antibiotics consumption, and the correlation between procalcitonin testing and antibiotics prescription. The cohort included 8666 patients, with mean age 45. 3ā€‰+/-ā€‰19. 9 years, 48. 5% male, and comorbidities in 26. 9%. Among 2688 patients with bacterial cultures performed, 147 (5. 5%) had bacterial co-infections, and 222 (8. 3%) had secondary bacterial infections. Antibiotics were prescribed for 2773 (32. 0%) patients during the hospital admission. Procalcitonin tests were performed for 2543 (29. 3%) patients. More patients with procalcitonin testing received antibiotics (65. 9% vs. 17. 9%, pā€‰

Open Access PDF

Concepts Keywords
Antibiotics Antibiotics stewardship
Covid Bacterial Infections
Drugs COVID-19
Laboratory Procalcitonin

Semantics

Type Source Name
disease MESH Bacterial infections
disease MESH COVID-19
disease MESH co-infections
disease MESH infections
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease MESH viral infections
disease MESH influenza
disease MESH respiratory tract infections
disease MESH urinary tract infections
disease MESH critically ill
disease IDO blood
disease VO population
disease VO report
drug DRUGBANK L-Alanine
drug DRUGBANK Creatinine
disease VO organization
disease IDO infection
disease MESH Hypertension
disease MESH Obesity
disease MESH Cardiovascular diseases
disease MESH Liver diseases
disease MESH Psychiatric disorders
disease MESH malignancy
disease MESH Pulmonary diseases
disease MESH comorbidity
disease MESH bloodstream infection
disease MESH hematological diseases
disease MESH death
disease VO Rho
disease IDO immunosuppression
disease MESH bacterial pneumonia
disease VO protocol
disease VO time
disease VO effectiveness
drug DRUGBANK Indoleacetic acid
disease MESH bacteriuria
disease MESH Pneumonia
disease IDO secondary infection
drug DRUGBANK Ranitidine
disease MESH healthcare associated Infections
drug DRUGBANK Trestolone

Original Article

(Visited 1 times, 1 visits today)